Focus: Rani Therapeutics is a public biotech company developing a proprietary oral delivery platform (RaniPill) to enable non-invasive administration of biologics, currently focused on metabolic diseases including obesity.
Profile data last refreshed 18h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Rani Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Rani Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Help build intelligence for Rani Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Rani Therapeutics Expands Oral Biologics Push With Obesity, Immunology Pipeline - Yahoo Finance
Rani Therapeutics Expands Oral Biologics Push With Obesity, Immunology Pipeline Yahoo Finance
RA Capital details 11,530,414 Rani Therapeutics (RANI) shares under 9.99% cap - Stock Titan
RA Capital details 11,530,414 Rani Therapeutics (RANI) shares under 9.99% cap Stock Titan
Rani Therapeutics Holdings, Inc. (RANI) awards 247,200 stock options to director - Stock Titan
Rani Therapeutics Holdings, Inc. (RANI) awards 247,200 stock options to director Stock Titan
Rani Therapeutics Holdings, Inc. (RANI) details director option holding - Stock Titan
Rani Therapeutics Holdings, Inc. (RANI) details director option holding Stock Titan
Former Arcellx CFO Joins Rani Therapeutics Board After Gilead Acquisition - Stock Titan
Former Arcellx CFO Joins Rani Therapeutics Board After Gilead Acquisition Stock Titan
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Average Rating of "Moderate Buy" from Analysts MarketBeat
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Oral delivery of an ustekinumab biosimilar with bioavailability comparable to subcutaneous administration in healthy human participants.
An oral robotic pill reliably and safely delivers teriparatide with high bioavailability in healthy volunteers: A phase 1 study.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo